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Abstract
Treatment of non-small cell lung cancer (NSCLC) with radiotherapy or chemoradiotherapy is often accompanied by the
development of esophagitis and pneumonitis. Identifying patients who might be at increased risk for normal tissue toxicity
would help in determination of the optimal radiation dose to avoid these events. We profiled 59 single nucleotide
polymorphisms (SNPs) from 37 inflammation-related genes in 173 NSCLC patients with stage IIIA/IIIB (dry) disease who were
treated with definitive radiation or chemoradiation. For esophagitis risk, nine SNPs were associated with a 1.5-to 4-fold increase
in risk, including three PTGS2 (COX2) variants: rs20417 (HR:1.93, 95% CI:1.10–3.39), rs5275 (HR:1.58, 95% CI:1.09–2.27), and
rs689470 (HR:3.38, 95% CI:1.09–10.49). Significantly increased risk of pneumonitis was observed for patients with genetic
variation in the proinflammatory genes IL1A, IL8, TNF, TNFRSF1B,a n dMIF. In contrast, NOS3:rs1799983 displayed a protective
effect with a 45% reduction in pneumonitis risk (HR:0.55, 95% CI:0.31–0.96). Pneumonitis risk was also modulated by
polymorphisms in anti-inflammatory genes, including genetic variationinIL13. rs20541 and rs180925 each resulted in increased
risk (HR:2.95, 95% CI:1.14–7.63 and HR:3.23, 95% CI:1.03–10.18, respectively). The cumulative effect of these SNPs on risk was
dose-dependent, as evidenced by a significantly increased risk of either toxicity with an increasing number of risk genotypes
(P,0.001). These results suggest that genetic variations among inflammation pathway genes may modulate the development
of radiation-induced toxicity and, ultimately, help in identifying patients who are at an increased likelihood for such events.
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Introduction
It was predicted that lung cancer would be diagnosed in over
215,000 individuals in the United States alone in 2008 [1].
Patients with locally advanced stage IIIA and IIIB (dry) disease
who are not candidates for surgery are treated with definitive
radiation therapy or combination chemoradiation therapy [2].
Unfortunately even with treatment, the overall 5-year survival rate
for NSCLC patients is only 10–15% [3].
One of the challenges in lung cancer treatment with
radiotherapy is the development of severe dose-limiting side
effects. Esophagitis and pneumonitis are common acute radiation-
induced normal tissue toxicities occurring in patients within one
year following treatment. Presence of these toxicities can also
cause a reduction in quality of life and may lead to chronic
complications including lung fibrosis [4]. Currently, there are few
predictors for the development of these toxicities based on clinical
and dosimetric parameters [5–9]. Therefore, the identification of
additional reliable markers could help to tailor radiation regimens
in order to administer the optimal therapeutic dose while
minimizing toxicity.
Inflammation is a physiological response to cellular and tissue
damage, including radiation-induced damage. Appropriate re-
sponse to this damage is tightly regulated through a balance
between proinflammatory and anti-inflammatory cytokines and
signaling molecules [10,11]. Genetic variation in key inflamma-
tion-related genes may cause a shift in balance resulting in
deregulation of the inflammatory response and corresponding
modulation of susceptibility to radiation-induced normal tissue
damage [12]. Previous studies have investigated genetic variation
in transforming growth factor-beta 1 (TGF-b1). This important
cytokine is up regulated following radiation exposure and common
variants located in TGFB1 have been found to be associated with
late normal tissue complications [13–17].
In this study, we utilized a pathway-based approach to analyze
genetic variation from 59 SNPs in 37 inflammation-related genes
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12402with regard to risk of developing either acute esophagitis or
pneumonitis following radiation therapy. We explored the main
effects of single SNPs and also the cumulative effect of genetic
variation within the inflammation pathway on toxicity risk. These
results indicate that an individual’s risk of developing these severe
sideeffectsmaybemodulatedbygermline variationininflammation
genes and may help to personalize radiation therapy for NSCLC.
Results
Patient Characteristics
A total of 173 non-Hispanic Caucasian patients with stage IIIA
(n=70 or 40.5%) or IIIB (dry) (n=103 or 59.5%) were included in
the analysis (Table 1). Of these patients, 91 (52.6%) were men
and 82 (47.4%) were women with a median age of 63.6 years.
Most of the patients had a history of smoking with 46.8% (n=81)
being former smokers and 46.2% (n=80) currently smoking or
having quit within a year prior to diagnosis. Sixty-three (36.4%) of
the tumors were classified as squamous cell carcinoma, 59 (34.1%)
as adenocarcinoma, and 40 (23.1%) as non-small cell carcinoma,
with the remainder (11 or 6.4%) as other NSCLC. Twenty-two
patients were given a pre-treatment ECOG performance score
$2. Nearly 80% (n=138) of the patients received combination
chemoradiation therapy, primarily with cisplatin or carboplatin
(n=142). A majority were treated with 3D radiotherapy (n=72 or
41.6%). There were 78 occurrences of grade $2 esophagitis and
Table 1. Patient characteristics.
Esophagitis Pneumonitis
Overall Grade ,2 n(%) Grade $2 n(%) P value Grade ,2 n(%) Grade $2 n(%) Pv alue
Gender
Male 91 50(52.63) 41(52.56) 73(56.15) 18(41.86)
Female 82 45(47.37) 37(47.44) 0.993 57(43.85) 25(58.14) 0.104
Total 173 95 78 130 43
Age, mean(SD) 63.60(9.98) 64.85(10.14) 62.08(9.64) 0.069 64.18(10.02) 61.86(9.78) 0.188
Smoking status
Never 12 6(6.32) 6(7.69) 8(6.15) 4(9.30)
Former 81 47(49.47) 34(43.59) 53(40.77) 28(65.12)
Current & Recent Quitter 80 42(44.21) 38(48.72) 0.733 69(53.08) 11(25.58) 0.007
Total 173 95 78 130 43
Packyr, mean(SD) 51.62(28.67) 53.67(28.37) 49.08(29.04) 0.315 53.71(29.41) 45.07(25.48) 0.102
Histology
Adenocarcinoma 59 26(27.37) 33(42.31) 42(32.31) 17(39.53)
Squamous Cell Carcinoma 63 41(43.16) 22(28.21) 48(36.92) 15(34.88)
Non-small Cell Carcinoma 40 21(22.11) 19(24.36) 33(25.38) 7(16.28)
Other NSCLC 11 7(7.37) 4(5.13) 0.118 7(5.38) 4(9.30) 0.481
Total 173 95 78 130 43
Clinical stage
Stage IIIA 70 41(43.16) 29(37.18) 46(35.38) 24(55.81)
Stage IIB(dry) 103 54(56.84) 49(62.82) 0.425 84(64.62) 19(44.19) 0.018
Total 173 95 78 130 43
Performance status
0 52 23(24.21) 29(37.18) 38(29.23) 14(32.56)
1 99 59(62.11) 40(51.28) 75(57.69) 24(55.81)
2–4 22 13(13.68) 9(11.54) 0.180 17(13.08) 5(11.63) 0.908
Total 173 95 78 130 43
Treatment
Radiation 35 31(32.63) 4(5.13) 29(22.31) 6(13.95)
Chemoradiation 138 64(67.37) 74(94.87) ,0.0001 101(77.69) 37(86.05) 0.237
Total 173 95 78 130 43
Radiation type
2D 55 36(37.89) 19(24.36) 47(36.15) 8(18.60)
3D 72 29(30.53) 43(55.13) 46(35.38) 26(60.47)
IMRT 46 30(31.58) 16(20.51) 0.005 37(28.46) 9(20.93) 0.013
Total 173 95 78 130 43
Radiation dose, mean(SD) 62.34(10.40) 60.75(12.64) 64.27(6.29) 0.026 61.68(11.63) 64.32(4.66) 0.149
doi:10.1371/journal.pone.0012402.t001
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these patients had both esophagitis and pneumonitis, while 75
patients had neither.
There were no significant differences between patients who
developed severe esophagitis and those who did not with regard to
age, gender, smoking status, histology, clinical stage and
performance status. However, patients who developed esophagitis
were more likely to receive chemoradiation instead of radiation
alone (P,0.001), and more likely to receive a higher mean
radiation dose (P=0.026) compared to those who did not develop
esophagitis. Interestingly, severe pneumonitis was more frequent
in patients who were former smokers compared to current smokers
or recent quitters (P=0.007). Patients with stage IIIA patients
were also more likely to develop pneumonitis (P=0.018). For both
esophagitis and pneumonitis, there was a significant difference in
the occurrence of toxicity by the type of radiation therapy
administered (P=0.005 and 0.013, respectively).
Inflammation-related SNPs and Risk of Esophagitis
Among the 59 SNPs studied, a total of nine inflammation-
related SNPs were found to be significantly associated with risk of
esophagitis following radiation treatment (Table 2). All of these
variants remained significant at an FDR level of 10%. In addition,
because esophagitis typically presents 4–6 weeks following
initiation of radiation therapy, we also analyzed the effect of these
variants using logistic regression. The results are similar to those
from the Cox regression analysis (data not shown).
Proinflammatory Genes. Of these nine SNPs, six were
among genes involved in the proinflammatory response: IL6, IL16,
TNF, and PTGS2 (COX2). Interleukin 6 (IL6):rs1800795 resulted
in an 2.16-fold increased risk (95% CI:1.18–3.94) under the
recessive model. A similar effect was observed for
IL16:rs11556218 (HR:2.28, 95% CI:1.16–4.47). Patients with at
least one tumor necrosis factor-a (TNF) variant rs1799724 had a
nearly 2-fold increased risk (HR:1.97, 95% CI:1.10–3.50). Three
SNPs in PTGS2 modulated esophagitis risk in our patient
population: rs20417, rs5275, and rs689470. PTGS2:rs5275 was
associated with an increased risk (P for trend =0.014). For
rs20417 and rs689470, carriers of at least one variant allele were at
an increased risk (HR:1.93, 95% CI:1.10–3.39 and HR:3.38, 95%
CI:1.09–10.49, respectively).
Anti-inflammatory Genes. SNPs in the IL4 receptor, IL10,
and the alpha subunit of the IL10 receptor were found to be
significantly associated with increased esophagitis risk. The
IL10:rs1800872 and IL10RA:rs3135932 variants were both
associated with significantly increased risks under the additive

















Proinflammatory cytokines, receptors, and related molecules
IL6:rs1800795 94 76 PTGS2:rs20417 94 76
CC 32(34.0) 30(39.5) 1.00 GG 82(87.2) 54(71.1) 1.00
CG 53(56.4) 27(35.5) 0.67 0.38 to 1.18 0.162 GC 12(12.8) 20(26.3) 1.90 1.07 to 3.39 0.029
GG 9(9.6) 19(25.0) 1.70 0.87 to 3.35 0.123 CC 0(0.0) 2(2.6)
CC+CG vs. GG 85 57 2.16 1.18 to 3.94 0.013 0.052 GC+CC 12 22 1.93 1.10 to 3.39 0.029 0.052
IL16:rs11556218 96 75 PTGS2:rs5275 92 75
TT 58(60.4) 41(54.7) 1.00 TT 51(55.4) 32(42.7) 1.00
TG 32(33.3) 22(29.3) 0.86 0.49 to 1.53 0.615 TC 39(42.4) 33(44.0) 1.43 0.85 to 2.39 0.178
GG 6(6.3) 12(16.0) 2.14 1.05 to 4.36 0.035 CC 2(2.2) 10(13.3) 2.71 1.25 to 5.88 0.011
TT+TG vs. GG 90 63 2.28 1.16 to 4.47 0.017 0.052 P for trend 1.58 1.09 to 2.27 0.014 0.052
TNF:rs1799724 92 71 PTGS2:rs689470 96 74
CC 74(80.4) 50(70.4) 1.00 CC 92(72.3) 70(94.6) 1.00
CT 12(13.0) 20(28.2) 2.13 1.17 to 3.86 0.013 CT 4(4.2) 3(4.1) 2.67 0.73 to 9.96 0.136 0.072
TT 6(6.5) 1(1.4) 0.91 0.12 to 6.99 0.928 TT 0(0.0) 1(1.4)
CT+TT 18 21 1.97 1.10 to 3.50 0.022 0.052 CT+TT 4 4 3.38 1.09 to 10.49 0.035
Anti-inflammatory cytokines, receptors, and related molecules
IL4R:rs1801275 94 75 IL10RA:rs3135932 95 76
AA 60(63.8) 40(53.3) 1.00 AA 68(71.6) 43(56.6) 1.00
AG 34(36.2) 28(37.3) 0.99 0.58 to 1.68 0.973 AG 24(25.3) 28(36.8) 1.38 0.83 to 2.28 0.217
GG 0(0.0) 7(9.3) GG 3(3.2) 5(6.6) 2.60 0.99 to 9.83 0.053
AA+AG vs. GG 94 68 4.12 1.60 to 10.59 0.003 0.052 P for trend 1.49 1.01 to 2.20 0.046 0.083
IL10:rs1800872 94 75
CC 65(69.1) 43(57.3) 1.00
CA 27(28.7) 26(34.7) 1.59 0.93 to 2.72 0.093
AA 2(2.1) 6(8.0) 2.88 1.15 to 7.22 0.024
P for trend 1.65 1.11 to 2.45 0.013 0.052
*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.
doi:10.1371/journal.pone.0012402.t002
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1.01–2.20), respectively. IL4R:rs1801275 resulted in over a 4-fold
increased risk (HR:4.12, 95% CI:1.60–10.59).
Joint Analysis of Esophagitis Risk Alleles. To understand
the cumulative effect of unfavorable genotypes on risk of
esophagitis, we performed a combined analysis. We included all
significant SNPs identified from our individual SNP analysis and
an additional seven SNPs reaching borderline significance at
p,0.10 (Table 3). Patients with four unfavorable genotypes had a
3.71-fold increased risk (95% CI:1.53–8.99) compared to those
with 0,3 unfavorable genotypes. This risk increased to 8.85 (95%
CI:4.19–18.68) for patients with five or more unfavorable
genotypes. Furthermore, patients with an increasing number of
unfavorable genotypes developed esophagitis significantly quicker
following initiation of radiation therapy (Figure 1A). Carriers of
five or more unfavorable genotypes had a median time to event of
only 1.1 months compared to over 12 months for those with three
or less unfavorable genotypes (P,0.0001).
Inflammation-related SNPs and Risk of Pneumonitis
A different set of inflammation-related SNPs was found to be
significantly associated with risk of developing pneumonitis
following radiation therapy and remained so at an FDR of 10%
(Table 4). Only one of the 12 SNPs identified were also associated
with esophagitis risk – TNF:rs1799724. Patients homozygous for
this variant exhibited a 5.96-fold increased risk (95% CI:1.33–
18.57) of pneumonitis. This risk is similar for esophagitis risk in
patients carrying at least one variant allele (Table 2).
Proinflammatory Genes. Other significant genetic variants
associated with pneumonitis included six SNPs in
proinflammatory genes, including IL1A, IL8, TNFRSF1B, MIF,
and NOS3. Two SNPs in IL1A – rs1800587 and rs17561– are in
strong linkage disequilibrium and each resulted in a more than
doubling of risk with HRs of 2.90 (95% CI:1.34–6.25) and 2.51
(95% CI:1.19–5.27), respectively. The risk associated with
IL8:rs4073 was similar at 3.16-fold (95% CI:1.54–6.48). Under
the additive model, TNFRSF1B:rs1061622 resulted in a 2.12-fold
increased risk (95% CI:1.18–3.79). A SNP in the lymphokine gene
MIF resulted in an even higher HR of 3.96 (95% CI:1.04–15.12).
In contrast, genetic variation in NOS3 was associated with a 50%
decrease in pneumonitis risk (HR:0.55, 95% CI:0.31–0.96). This
was the only SNP in our analysis to be significantly associated with
a reduction in risk.
Anti-inflammatory Genes. IL4 and IL13 share a common
receptor and have many of the same anti-inflammatory functions.
In our population, we found that genetic variations in both of these
interleukins were associated with increased risks of developing
pneumonitis. The two IL4 SNPs each resulted in increased risk
with HRs of 2.54 (95% CI:1.27–5.08) and 3.05 (95% CI:1.50–
6.22), respectively. IL13 polymorphisms had a similar effect on
pneumonitis risk. Patients with two variant alleles or either
rs20541 or rs180925 were approximately 3-times more likely to
develop pneumonitis compared to those with wild-type or
heterozygous genotypes (HR:2.95, 95% CI:1.14–7.63 and
HR:3.23, 95% CI:1.03–10.18). The signaling molecule IkappaB-
alpha (NFKBIA) inhibits the inflammatory response by blocking
NFkappaB-mediated transcription of proinflammatory genes.
NFKBIA:rs8904 resulted in a 2.02-fold increased pneumonitis
risk (95% CI:1.01–4.03).
Joint Analysis of Pneumonitis Risk Alleles. In combined
analysis, the significant SNPs together with an additional
borderline significant variant – IL4R: rs1801275 (P=0.053) –
showed an increase in pneumonitis risk as the number of
unfavorable genotypes increased (Table 3). The increased risk
for carrying three unfavorable genotypes was 13.30-fold compared
to patients with 0 to 2 risk genotypes (P=0.013). This risk was
dramatically increased for the group of patients with four or more
unfavorable genotypes (P,0.0001). These high risk individuals
also had a shorter duration between start of treatment and
development of pneumonitis of only 5.33 months compared to
over 12 months for those with 0 to 2 unfavorable genotypes
(Figure 1B).
Inflammation-related SNPs and Overall Survival
The development of toxicity and survival are often related since
patients who develop toxicity are those who are responding to
treatment. Therefore, we determined if any of the variants
identified as toxicity risk factors were also associated with survival
Table 3. Cumulative effect of unfavorable genotypes and radiation-induced toxicity risk.
Number of Unfavorable Genotypes Grade ,2 n Grade $2 n *HR 95% CI P value
#Esophagitis
0,3 49 11 1.00
42 3 1 4 3.71 1.53 to 8.99 0.004
$51 6 4 2 8.85 4.19 to 18.68 ,0.0001
P trend ,0.0001
&Phenumonitis
0,2 41 1 1.00
35 8 1 7 13.30 1.72 to 102.94 0.013
$41 5 2 0 69.42 8.62 to 558.91 ,0.0001
P trend ,0.0001
*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen,
radiation type, and radiation dosage.
#unfavorable genotypes: IL6:rs1800795, IL16:rs11556218, TNF:rs1799724, PTGS2:rs20417.
PTGS2:rs5275, PTGS2:rs689470, IL4R:rs1801275, IL10:rs1800872, IL10RA:rs3135932.
IL1B:rs16944, IL2RB:rs228942, IL8:rs4073, IL10RB:rs2834167, IL13:rs1800925, NOS2:rs2297518.
&unfavorable genotypes: IL1A:rs1800587, IL8:rs4073, TNF:rs1799724, TNFRSF1B:rs1061622.
MIF:rs7555622, IL4:rs2243250, IL4R:rs2070874, IL13:rs10800925, IL13:rs20541, NOS3:rs1799983, NFKBIA:rs1799983.
doi:10.1371/journal.pone.0012402.t003
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allele of IL10:rs1800872 had a 1.74-fold increased risk of
esophagitis, but a 40% decreased risk of dying when compared
to patients with wild-type genotypes (HR:0.62, 95% CI:0.40–
0.97). Figure 2A illustrates the time to esophagitis for patients
with IL10:rs1800872 genotypes. Although not significant, patients
with wild-type genotypes had median time to event of greater than
12 months contrasted with only 1.8 months for those with at least
one variant of rs1800872. For survival (Figure 2B), there was a
non-significant survival advantage of nearly four months for
carriers with a median survival time of 16.1 months compared to
only 12.4 months for patients with wild-type genotypes.
Discussion
In this study, we systematically analyzed 59 common genetic
variations in inflammation-related genes for association with risk of
developing acute esophagitis or pneumonitis following radiation
treatment in NSCLC patients. Multiple individual SNPs inimportant
pro- and anti-inflammatory genes were identified as modulating risk
for both normal tissue toxicities. Furthermore, the cumulative effect
of these SNPs was dose-dependent with individuals carrying multiple
unfavorable alleles having a corresponding increase in risk.
Nine genetic variants were identified as significantly associated
with esophagitis risk, and of those, six were in proinflammatory
genes (Table 2). We found that rs1800795 in IL6 resulted in a
2.16-fold increase in esophagitis. This polymorphism is located
within the 59-untranslated region of IL6 and has been functionally
studied with conflicting results of the effect on gene expression and
response to stimulation [18,19]. However, a recent meta-analysis
of over 5,500 patients was not able to demonstrate a relationship
between this variant and IL6 serum levels [20]. Gao et al.
demonstrated that IL16:rs11556218 was significantly associated
with colorectal and gastric cancer, but did not observe a
correlation between IL16 serum levels measured in these patients
and rs11556218 [21]. PTGS2:rs20417 was also associated with
increased risk of esophagitis. This promoter variant disrupts a
Sp1/Sp3 transcription factor binding site and causes a decrease in
transcriptional activity in lung fibroblast cells [22,23]. Decreased
expression of COX2 would suggest a decrease in inflammation
signaling. However, this same variant, while altering the Sp1/Sp3
site, also introduces a binding site for another transcription factor,
Egr-1, although the consequences are unknown [22]. The other
two significant variants (rs5275 and rs689470) are located in the
39-UTR and regulate PSTGS2 mRNA levels. Our results suggest
that these SNPs are linked with an increase in pro-inflammatory
Figure 1. Event-free survival by number of unfavorable genotypes in inflammation-related genes. Kaplan-Meier curves of freedom from
(A) grade .2 esophagitis or (B) grade .2 pneumonitis following radiation therapy. Numbers in parentheses are the number of patients with toxicity
over the total number of patients; time is median event-free duration in months.
doi:10.1371/journal.pone.0012402.g001
NSCLC Radiation Toxicity
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12402activity leading to esophagitis. Further functional analysis is
warranted to understand the underlying mechanisms [24].
For anti-inflammatory molecules and esophagitis risk, Khurana
Hershey et al. demonstrated that IL4R:rs1801275 resulted in
enhanced IL4 signaling and the induction of high levels of the IgE
receptor CD23 [25]. IL10:rs1800872 and IL10RA:rs3135932
have been shown to decrease IL10 signaling by decreasing serum
levels and altering IL10-IL10RA interactions, respectively [26,27].
The reported functions of these three SNPs would be in agreement
with our findings of an increased risk of esophagitis by decreasing
the anti-inflammatory response.
Twelve common polymorphisms were found to be significantly
associated with risk of pneumonitis. The two IL1A variants are in
linkage disequilibrium and were found to increase risk by nearly 3-
fold. IL1A:rs1800587 has been shown to contribute to an increase
in IL1-a promoter activity, mRNA levels and protein levels [28].
IL1A:rs17561 is a non-synonymous SNP and increases processing
of the IL1-a precursor resulting in an increase in the levels of
active IL1-a [29]. The variant of IL8:rs4073, which was found to
increase pneumonitis risk 3-fold, has been associated with
increased secretion of the proinflammatory cytokine IL8 [30].
IL4 and IL13 work together to regulate the inflammatory
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Proinflammatory cytokines, receptors, and related molecules
IL1A:rs1800587 128 43 TNFRSF1B:rs1061622 126 42
CC 65(50.8) 11(25.6) 1.00 TT 72(57.1) 17(40.5) 1.00
CT 51(39.8) 30(69.8) 3.66 1.66 to 8.07 0.001 TG 50(39.7) 22(52.4) 1.84 0.90 to 3.79 0.096
TT 12(9.4) 2(4.7) 0.89 0.19 to 4.23 0.885 GG 4(3.2) 3(7.1) 5.88 1.50 to 23.09 0.011
CT+TT 63 32 2.90 1.34 to 6.25 0.007 0.021 P for trend 2.12 1.18 to 3.79 0.012 0.023
IL1A:rs17561 128 43 MIF:rs755622 126 43
GG 65(50.8) 12(27.9) 1.00 CC 89(70.6) 26(60.5) 1.00
GT 52(40.6) 29(67.4) 3.11 1.44 to 6.72 0.004 CG 32(25.4) 12(27.9) 1.49 0.69 to 3.24 0.312
TT 11(8.6) 2(4.7) 0.85 0.18 to 4.01 0.836 GG 5(4.0) 5(11.6) 4.49 1.14 to 17.66 0.031
GT+TT 63 31 2.51 1.19 to 5.27 0.015 0.024 CC+CG vs. GG 121 38 3.96 1.04 to 15.12 0.044 0.038
IL8:rs4073 128 41 NOS3:rs1799983 129 42
TT 37(28.9) 7(17.1) 1.00 GG 51(39.5) 22(52.4) 1.00
TA 66(51.6) 19(46.3) 1.35 0.51 to 3.56 0.548 GT 61(47.3) 17(40.5) 0.53 0.27 to 1.04 0.067
AA 25(19.5) 15(36.6) 3.88 1.42 to 10.62 0.008 TT 17(13.2) 3(7.1) 0.34 0.08 to 1.51 0.157
TT+TA vs. AA 103 26 3.16 1.54 to 6.48 0.002 0.010 P for trend 0.55 0.31 to 0.96 0.037 0.038
TNF:rs1799724 121 42
CC 94(77.7) 30(71.4) 1.00
CT 23(19.0) 9(21.4) 1.45 0.64 to 3.26 0.370
TT 4(3.3) 3(7.1) 5.32 1.40 to 20.22 0.014
CC+CT vs. TT 117 39 4.96 1.33 to 18.57 0.017 0.024
Anti-inflammatory cytokines, receptors, and related molecules
IL4:rs2243250 128 42 IL13:rs20541 129 43
CC 103(80.5) 27(64.3) 1.00 CC 88(68.2) 28(65.1) 1.00
CT 22(17.2) 13(31.0) 2.50 1.22 to 5.11 0.012 CT 35(27.1) 9(20.9) 0.98 0.43 to 2.25 0.968
TT 3(2.3) 2(4.8) 3.10 0.34 to 28.02 0.313 TT 6(4.7) 6(14.0) 2.94 1.12 to 7.73 0.028
CT+TT 25 15 2.54 1.27 to 5.08 0.008 0.021 CC+CT vs. TT 123 37 2.95 1.14 to 7.63 0.025 0.031
IL4:rs2070874 128 43 IL13:rs180925 129 43
CC 104(81.3) 27(62.8) 1.00 CC 83(64.3) 26(60.5) 1.00
CT 21(16.4) 15(34.9) 3.09 1.49 to 6.44 0.003 CT 42(32.6) 13(30.2) 0.71 0.33 to 1.52 0.380
TT 3(2.3) 1(2.3) 2.59 0.27 to 24.47 0.405 TT 4(3.1) 4(9.3) 2.97 0.93 to 9.45 0.066
CT+TT 24 16 3.05 1.50 to 6.22 0.002 0.010 CC+CT vs. TT 125 39 3.23 1.03 to 10.18 0.045 0.038
NFKBIA:rs8904 127 43
CC 54(42.5) 12(27.9) 1.00
CT 53(41.7) 16(37.2) 0.99 0.42 to 2.30 0.974
TT 20(15.7) 15(34.9) 2.00 0.84 to 4.79 0.119
CC+CT vs. TT 107 28 2.02 1.01 to 4.03 0.047
*adjusted for age, gender, pack years, clinical stage, performance status, treatment regimen, radiation type, and radiation dosage.
doi:10.1371/journal.pone.0012402.t004
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with ,3-fold increased risk of pneumonitis. Studies have
demonstrated increased IgE production for IL4:rs2070874 and
rs2243250 [31] and increased IL13 activity for IL13:rs20541 and
rs180925 [32,33].
Genetic variation in TNF and the receptor TNFRSF1B were also
associated with increased risk of pneumonitis. TNF-a signaling is
an important modulator of the inflammatory response. The
TNF:rs1799724 variant is located within the promoter region of
the gene and thought to influence gene expression by creating an
OCT-1 transcription factor binding site [34]. The effect of this
differential binding on TNF-a signaling is not clear. Some studies
have shown an increase in TNF-a production [35,36,37], while
others have shown the opposite effect [38,39,40]. For TNFRSF1B,
the non-synonymous variant Met196Arg (rs1061622) does not
alter TNF-a binding affinity, but results in intensified TNF-a
signaling [41] and decreased NF-kB signaling [42].
Only one genetic variant was found to confer a protective effect
following radiotherapy. This variant, rs1799983, in NOS3 was
associated with a 70% reduction in risk of pneumonitis. Functional
studies have demonstrated that this variant results in production of
a variant allozyme with reduced enzyme activity [43] resulting in a
reduction in nitric oxide production [44]. These observations
support our findings of decreased pneumonitis due to decreased
inflammatory signaling.
In all, the functional consequences of the variants identified as
strongly associated with increased risk of normal tissue toxicity
following radiation exposure suggest a high biological plausibility
for our findings. However, little to no information is known about
how these variants specifically alter pneumonitis and esophagitis
risk. The inflammatory response is complex and many prototypic
‘‘proinflammatory’’ molecules have anti-inflammatory attributes
under specific conditions, and vice versa. Further studies are
warranted to elucidate the specific function of these SNPs in target
tissues following exposure to radiation.
Interestingly, we observed several variants with a trend towards
a relationship between toxicity and overall survival, and only one
SNP was identified as being associated with both. This result
Figure 2. Relationship between esophagitis and overall survival. (A) Kaplan-Meier curves of freedom from grade .2 esophagitis following
radiation therapy by IL10:rs1800872 genotypes. Numbers in parentheses are the number of patients with toxicity over the total number of patients;
time is median event-free duration in months. (B) Kaplan-Meier curves of overall survival following radiation therapy by IL10:rs1800872 genotypes.
Numbers in parentheses are the number of patients alive over the total number of patients; time is median survival time in months.
doi:10.1371/journal.pone.0012402.g002
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dbSNP ID Alleles Gene Symbol Gene Name SNP Location*
rs1800872 C/A IL10 interleukin 10 5’-FR
rs1800896 G/A IL10 interleukin 10 5’-FR
rs1900871 A/C IL10 interleukin 10 5’-FR
rs3135932 A/G IL10RA interleukin 10 receptor, alpha Ser159Gly
rs2834167 A/G IL10RB interleukin 10 receptor, beta Lys47Glu
rs1800925 C/T IL13 interleukin 13 5’-FR
rs20541 C/T IL13 interleukin 13 Arg130Gln
rs2070874 C/T IL4 interleukin 4 5’-UTR
rs2243250 C/T IL4 interleukin 4 5’-FR
rs1801275 A/G IL4R interleukin 4 receptor Gln576Arg
rs1805010 A/G IL4R interleukin 4 receptor Ile75Val
rs1805011 A/C IL4R interleukin 4 receptor Glu400Ala
rs1805015 T/C IL4R interleukin 4 receptor Ser503Pro
rs1805016 T/G IL4R interleukin 4 receptor Ser752Ala
rs2069812 C/T IL5 interleukin 5 receptor 5’-FR
rs2233409 C/T NFKBIA IkB alpha 5’-FR
rs8904 C/T NFKBIA IkB alpha 3’-UTR
rs1800206 C/G PPARA peroxisome proliferator-activated receptor alpha Leu162Val
rs2016520 A/G PPARD peroxisome proliferator-activated receptor delta 5’-UTR
rs1801282 C/G PPARG peroxisome proliferator-activated receptor gamma Pro12Ala
rs1024611 T/C CCL2 chemokine (C-C motif) ligand 2 5’-FR
rs2069614 C/T CSF2 colony stimulating factor 2 (granulocyte-macrophage) 5’-FR
rs25882 T/C CSF2 colony stimulating factor 2 (granulocyte-macrophage) Ile117Thr
rs2257167 G/C IFNAR1 interferon (alpha, beta and omega) receptor 1 Val168Leu
rs1051393 T/G IFNAR2 interferon (alpha, beta and omega) receptor 2 Phe10Val
rs2069705 T/C IFNG interferon, gamma 5’-FR
rs2430561 A/T IFNG interferon, gamma intron
rs3212227 A/C IL12B interleukin 12B 3’-UTR
rs375947 A/G IL12RB interleukin 12 receptor, beta 1 Met365Thr
rs11556218 T/G IL16 interleukin 16 Asn446Lys
rs4778889 T/C IL16 interleukin 16 5’-FR
rs17561 G/T IL1A interleukin 1, alpha Ala114Ser
rs1800587 C/T IL1A interleukin 1, alpha 5’-FR
rs1143627 T/C IL1B interleukin 1, beta 5’-FR
rs1143634 C/T IL1B interleukin 1, beta Phe105Phe
rs16944 C/T IL1B interleukin 1, beta 5’-FR
rs2228139 C/G IL1R1 interleukin 1 receptor, type I Ala124Gly
rs2069762 T/G IL2 interleukin 2 5’-FR
rs228942 C/A IL2RB interleukin 2 receptor, beta Asp391Glu
rs1800795 C/G IL6 interleukin 6 (interferon, beta 2) 5’-FR
rs2228145 A/C IL6R interleukin 6 receptor Asp358Ala
rs4073 T/A IL8 interleukin 8 5’-FR
rs2234671 G/C IL8RA interleukin 8 receptor, alpha Ser276Thr
rs2229092 A/C LTA lymphotoxin alpha His51Pro
rs2229094 T/C LTA lymphotoxin alpha Arg13Cys
rs755622 C/G MIF macrophage migration inhibitory factor 5’-FR
rs1799724 C/T TNF tumor necrosis factor 5’-FR
rs1799964 T/C TNF tumor necrosis factor 5’-FR
rs1800629 G/A TNF tumor necrosis factor 5’-FR
rs361525 G/A TNF tumor necrosis factor 5’-FR
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toxicity are responding well to therapy with longer survival times.
Unfortunately, these side effects are dose limiting and often result
in cessation of treatment. It may be that these select patients would
receive the most benefit from the inclusion of radioprotective
agents such as amifostine and glutamine in their treatment
regimen. Both work by decreasing the levels of reactive oxygen
species in the exposed normal tissue and, thus, potentially avoiding
the development of inflammation. It would be of interest to test the
significant SNPs identified in this study within the framework of
these agents.
Our study has several advantages, including the patient
population with availability of comprehensive clinical and
epidemiological information. To our knowledge, no study has
systematically investigated the effect of genetic variations within
inflammation-related genes and risk of normal tissue toxicity
due to radiation therapy. This pathway-based approach allowed
us to comprehensively elucidate the cumulative effects of
multiple adverse alleles on toxicity risk. Since a patient’s
genome can contain several of these risk associated genetic
variants in both proinflammatory and anti-inflammatory
pathways, this approach is much more powerful in detecting
the effect of these SNPs on a patient’s risk of developing
esophagitis or pneumonitis. The variants included in this study
were candidate SNPs based on known or predicted effects on
gene function. A candidate-gene approach has the advantage of
being anchored by known biological plausibility, but there is a
possibility that this study has missed additional risk alleles or
detected a variant in linkage disequilibrium with the true
causative SNP. In addition, we were not able to include
additional variables that may also impact toxicity, including
radiation field size, dose to organ at risk (esophagus and lung),
treatment volume, and tumor location.
In conclusion, we identified several biologically plausible
associations between genetic variants in important inflammation-
related genes and risk of developing esophagitis and pneumonitis.
We also demonstrated a dose-effect of inflammation SNPs as
evidenced by the dramatic increases in risk with increases in
number of unfavorable genotypes. Furthermore, we identified one
variant in IL10 that is associated with increased risk of esophagitis,
but a decreased risk of dying. Since radiotherapy is a mainstay of
lung cancer treatment, having the ability to screen patients prior to
initiation of treatment would potentially minimize these acute
toxicity events while allowing for higher doses of radiation for
those who are not at increased risk in order to improve local
control. With validation, these results, together with clinical and
dosimetric predictors, could serve to increase the overall benefit of
radiation therapy in NSCLC patients.
Methods
Ethics Statement
Participants gave written informed consent and the study was
approved by The University of Texas MD Anderson Cancer
Center’s Institutional Review Board.
Patient Population
The study included non-Hispanic Caucasian subjects who were
newly diagnosed, histologically confirmed stage IIIA or IIIB
without a malignant effusion (dry) NSCLC patients receiving
definitive thoracic radiation or chemoradiation therapy at The
University of Texas MD Anderson Cancer Center. All of the
patients were enrolled in an ongoing epidemiology lung cancer
study between 1995 and 2007.
Epidemiological and Clinical Data Collection
Epidemiologic data were collected during an in-person interview
using a structured questionnaire to determine demographic
characteristics, medical history, and smoking history. Clinical and
follow-up information was abstracted from medical records. Pre-
treatment performance status was determined based on the Eastern
Cooperative Oncology Group scale. Radiation-induced esophagitis
was characterized by documentation of new-onset pain on
swallowing occurring during treatment. Pneumonitis was detected
by roentgenographic or CT scan abnormalities and often associated
with nonproductive cough and/or fever. Severity of pneumonitis or
esophagitis was scored by the physician according to National
CancerInstituteCommonTerminologyCriteriaforAdverseEvents
(version 3.0) guidelines [45]. For this study, an event was considered
the occurrence of grade $2 toxicity.
SNP Selection and Genotyping
Blood was drawn from each participant following the in-person
interview. These samples were used to extract genomic DNA from
peripheral blood lymphocytes using the Human Whole Blood
Genomic DNA Extraction Kit (Qiagen, Valencia, CA). A total of
59 candidate SNPs (Table 5) were selected from 37 known
inflammation-related genes as previously described [46]. Briefly,
candidate SNPs were selected if they had a minor allele frequency
dbSNP ID Alleles Gene Symbol Gene Name SNP Location*
rs4149570 G/T TNFRSF1A tumor necrosis factor receptor superfamily, member 1A 5’-FR
rs4149584 G/A TNFRSF1A tumor necrosis factor receptor superfamily, member 1A Arg121Gln
rs1061622 T/G TNFRSF1B tumor necrosis factor receptor superfamily, member 1B Met196Arg
rs5746026 G/A TNFRSF1B tumor necrosis factor receptor superfamily, member 1B Glu232Lys
rs2297518 G/A NOS2 nitric oxide synthase 2, inducible Leu608Ser
rs1799983 G/T NOS3 nitric oxide synthase 3 (endothelial cell) Glu298Asp
rs20417 G/C PTGS2 prostaglandin-endoperoxide synthase 2 5’-FR
rs5275 T/C PTGS2 prostaglandin-endoperoxide synthase 2 3’-UTR
rs689470 C/T PTGS2 prostaglandin-endoperoxide synthase 2 3’-UTR
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of the gene (promoter, untranslated regions (UTR) or exons) or
had previously been reported as associated with cancer or an
inflammatory disorder. Genotyping was performed using the
SNPlex assay following manufacturer’s instructions (Applied
Biosystems, Foster City, CA) with analysis on an Applied
Biosystems 3730 DNA Analyzer. SNP genotypes were called
using the GeneMapper software (Applied Biosystems). Three
SNPs: IL8RA:rs2234671, LTA:rs2229092 and IL4R:rs1805011
were removed because of excessive missing genotypes (.20%). All
genotyping was completed blinded with regard to toxicity status.
Statistical Analysis
Time to event (grade $2 pneumonitis or esophagitis) was based
on the duration from start of radiation treatment to occurrence of
toxicity. Three-year survival was also defined as the time from start
of radiation treatment to the date of death or the date of last
follow-up during the three year period. Hazard ratios (HRs) and
95% confidence intervals (95% CIs) for each individual SNP and
endpoint combination were estimated by fitting the Cox
proportional hazard model while adjusting for age, gender, clinical
stage, pack years of smoking, pre-treatment performance status,
treatment regimen (radiotherapy or chemoradiotherapy), radiation
type, and radiation dosage. Kaplan-Meier curves and log-rank
tests were used to assess differences in time to event and overall
survival rates. Combined effects of unfavorable genotypes were
based on the main effect analysis of individual SNPs and included
those with significant (P,0.05) and borderline significant (P,0.10)
associations. STATA software (version 10, STATA Corp., College
Station, TX) was used for statistical analyses. Q-values were
calculated to control for multiple comparisons based on an FDR
value of 10% [47].
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